ABEONA THERAPEUTICS INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ABEONA THERAPEUTICS INC. (ABEO) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $39.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-17
- ABEONA THERAPEUTICS INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $39.50M, a 631.48% increase from fiscal 2024.
- ABEONA THERAPEUTICS INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $5.40M, a 37.93% decline from fiscal 2023.
- ABEONA THERAPEUTICS INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $8.70M, a 8.42% decline from fiscal 2022.
- ABEONA THERAPEUTICS INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $9.50M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $39.50M 10-K · filed 2026-03-17 |
| 2024-12-31 | $5.40M 10-K · filed 2026-03-17 |
| 2023-12-31 | $8.70M 10-K · filed 2025-03-20 |
| 2022-12-31 | $9.50M 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |